VHL also showed a high expression level in most (16 of 33) tumor types and a low expression level in the majority of tissues, and it could interact with 1638 proteins, including EGFR, KRAS, and BCL2L1. Beyond the co-opted E3 ligases, 76 potentially novel E3 ligases also exhibit similar characteristics and may be incorporated into PROTAC development. The gene discussed is BCL2L1; the disease is neoplasm.